<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Yao, Min</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Concurrent Chemoradiotherapy Tolerated in Recurrent HNSCC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-12</style></pages><abstract><style  face="normal" font="default" size="100%">Due to the poor prognosis of recurrent head and neck squamous cell carcinoma (HNSCC), there is an imperative to identify a safe and tolerable therapy course. Despite the prevalence of combined radiotherapy and chemotherapy, an optimal therapeutic regimen has not been elucidated. This article discusses data from a multicenter prospective phase 2 study that looked at concurrent reirradiation and combined chemotherapy treatment for patients with HNSCC.</style></abstract><number><style face="normal" font="default" size="100%">31</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>